^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etoposide IV

    i
    Other names: VP-16, BMY 40481, BMY-40481
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    1d
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov)
    P1, N=328, Recruiting, HC Biopharma Inc.
    New P1 trial
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • etoposide IV
    3d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    3d
    Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells. (PubMed, Sci Rep)
    In the NEN cell lines BON-1, QGP-1, and MS-18, we applied cisplatin, etoposide, streptozotocin, 5-fluorouracil, temozolomide, and everolimus- all systemic agents used in highly proliferative NEN. These findings might have an impact on the optimal therapy sequence and patient selection for future CXCR4-targeted approaches. Further, the decreased CXCR4 expression could represent a new mechanism of action of the established drugs Cisplatin, Temozolomide, and Everolimus.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    cisplatin • 5-fluorouracil • everolimus • temozolomide • etoposide IV
    4d
    Efficacy of Low-Dose Etoposide Combined with PEG-G-CSF for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (ChiCTR2600115897)
    P=N/A, N=23, Recruiting, The Second Affiliated Hospital of Hainan Medical University; The Second Affiliated Hospital of Hainan Medical University
    New trial
    |
    etoposide IV
    4d
    The efficacy and safety of Huairu Granules combined with chemotherapy and immunotherapy as first-line treatment for extensive-stage small cell lung cancer: A single-arm, prospective, phase II study (ChiCTR2500114626)
    P4, N=60, Not yet recruiting, Huzhou Central Hospital; Huzhou Central Hospital
    New P4 trial
    |
    etoposide IV
    4d
    Toripalimab in combination with chemotherapy and lithium carbonate for first-line treatment of extensive-stage small cell lung cancer in stage Ib/II clinical research (ChiCTR2500113193)
    P2, N=51, Not yet recruiting, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University Affiliated Tumor Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi) • etoposide IV
    4d
    A Single-arm, Multi-center, Open-label Phase II Study to Investigate the Efficacy and Safety of Serplulimab in Combination with Chemotherapy in First-line Treatment of Pulmonary Neuroendocrine Carcinoma (ChiCTR2500113228)
    P2, N=162, Recruiting, PLA General Hospital; PLA General Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    carboplatin • etoposide IV • Hetronifly (serplulimab)
    4d
    Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR2500112838)
    P1/2, N=622, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    cisplatin • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • pemetrexed • etoposide IV • Hetronifly (serplulimab) • Enshuxing (enlonstobart)
    4d
    Postmenopausal Stage IV Ovarian Yolk Sac Tumor With Neuroendocrine Features: Report of a Rare Case. (PubMed, Anticancer Res)
    This case illustrates a particularly rare and aggressive presentation of ovarian YST in a postmenopausal patient. Early recognition, accurate pathological characterization, and individualized treatment are essential, although prognosis remains poor in this setting. Reporting such cases is crucial to improve understanding and management of these exceptional tumors.
    Journal
    |
    CHGA (Chromogranin A)
    |
    cisplatin • etoposide IV • bleomycin
    5d
    Neurological Involvement in Adult-Onset Secondary Hemophagocytic Lymphohistiocytosis: Clinical Features and Prognostic Implications. (PubMed, Brain Behav)
    CNS involvement defines a severe phenotype of adult-onset sHLH, characterized by malignancy-prone etiology, intense neuroinflammation, and poor prognosis. We establish CNS involvement as an independent predictor of mortality, underscoring the critical need for early recognition and CNS-directed therapies.
    Journal
    |
    IL6 (Interleukin 6)
    |
    etoposide IV • dexamethasone
    6d
    Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • carfilzomib • Truxima (rituximab-abbs)
    6d
    TRIPLEX: Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer (clinicaltrials.gov)
    P3, N=239, Terminated, Norwegian University of Science and Technology | Trial completion date: Oct 2029 --> Sep 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Sep 2025; Termination was adviced by Data Safety Committee due to excess toxicity of the experimental treatment.
    Trial completion date • Trial termination • Trial primary completion date
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV